Oncologists Clarify Limitations Of Tumour Markers In Screening

Medical oncologists are cautioning the public against misinterpreting tumour markers as standalone cancer screening tools. These biological markers, often proteins or substances found in blood, urine, or tissue, are primarily utilized to monitor cancer progression or treatment response rather than for routine screening in asymptomatic individuals. Oncologists emphasize that reliance on these markers for early detection can lead to significant psychological distress and unnecessary follow-up procedures without definitive diagnostic value.

The confusion often arises from direct-to-consumer health packages that bundle tumour marker tests into comprehensive health checkups. However, high levels of specific markers can be caused by benign conditions, infections, or inflammation, leading to false positives. Conversely, low levels do not guarantee the absence of cancer, potentially creating a false sense of security. Medical experts advocate for evidence-based screening protocols, which are tailored to individual risk factors rather than relying on generalized blood tests that lack the specificity required for effective cancer prevention.

For patients and the public, the path toward cancer awareness lies in regular checkups that focus on symptomatic screening and clinical examinations. The healthcare industry is now calling for better patient education to ensure that medical tests are interpreted within the correct clinical context. Moving forward, the emphasis should be on standard protocols that doctors determine based on family history, age, and lifestyle, rather than seeking out high-cost, low-accuracy tests. Adhering to professional medical guidance remains the safest approach for effective cancer management and timely intervention.